April 12, 2024
Scott Maucione


Maryland’s Prescription Drug Affordability Board is moving closer to putting price caps on as many as eight drugs in the near future.

The board selected a handful of drugs it thinks fit the criteria of being cost prohibitive to Marylanders who are on state-run health insurance plans.

The drugs include the diabetes and weight loss medication Ozempic, ADHD drug Vyvance and Dupixent, a medication that’s used to treat asthma.

Others selected are Trulicity, Jardiance, Farxiga, Skrizi and Bikarvy.

The selected medications are now going to the stakeholder council to be considered and where the public will have 30 days to comment on the selections.

Read the full article at WYPR.org

Last modified: April 16, 2024